Diabetic control and atypical antipsychotics: a case report by Gaston, Romina Lopez et al.
BioMed  Central
Page 1 of 4
(page number not for citation purposes)
Journal of Medical Case Reports
Open Access Case report
Diabetic control and atypical antipsychotics: a case report
Romina Lopez Gaston*, Mohan George and Nangai Azhahan
Address: Psychiatric Intensive Care Unit, Queen Elizabeth Psychiatric Hospital (University Hospital), Birmingham, UK
Email: Romina Lopez Gaston* - logaston1@hotmail.com; Mohan George - mohan.george@bsmht.nhs.uk; 
Nangai Azhahan - nazhahan@nhs.net
* Corresponding author    
Abstract
Introduction:  People with schizophrenia are at increased risk of developing metabolic
disturbances. This risk may be further exacerbated by the use of antipsychotic agents. Research is
still ongoing to determine the metabolic impact of antipsychotics on glucose regulation. In this case
report we review some of the possible mechanisms of action of antipsychotic medication on
glucose regulation.
Case presentation: We present the case of a 50-year-old man diagnosed with paranoid
schizophrenia who developed type 2 diabetes mellitus whilst on treatment with second generation
antipsychotics (SGA). His diabetes was controlled by a combination of antidiabetic drugs that were
associated with his psychotropic treatment. Due to deterioration in his mental state, the patient
was admitted on two occasions to a psychiatric unit during which his prescribed medication
(olanzapine and risperidone) was discontinued and changed to aripiprazole. On both occasions, the
patient suffered hypoglycaemic episodes and his antidiabetic treatment had to be adjusted
accordingly. The patient did not require any antidiabetic treatment whilst on aripiprazole during
the follow up period.
Conclusion: Clinicians face regular dilemmas in trying to find the right balance between achieving
control over a patient's mental illness and reducing any adverse effects associated with the
prescribed medication. In patients receiving concomitant antidiabetic therapy, caution should be
exercised when changing from one SGA to another. Whilst more longitudinal data are required, a
trial of alternative SGAs, including aripiprazole in those developing type 2 diabetes and impaired
glucose tolerance may be a worthwhile therapeutic option.
Introduction
Second generation antipsychotics (SGAS) have been
adopted as first line treatment for people with schizophre-
nia [1]. This has been based on a superior safety profile
with regards to adverse events such as extrapyramidal
symptoms in comparison to first generation (or 'conven-
tional') antipsychotics [2]. However, many studies have
provided convincing evidence for a high risk of metabolic
abnormalities associated with the use of some of these
agents [3]. These are of major concern owing to the addi-
tive effect on morbidity and mortality in a population
with already increased prevalence of obesity, type 2 diabe-
tes mellitus and cardiovascular disease [4].
The prevalence of diabetes mellitus among people with
schizophrenia is approximately two to four times higher
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than in the general population, and schizophrenia
appears to be an independent risk factor for diabetes mel-
litus [5]. The development of metabolic abnormalities
within an individual patient can depend on the contribu-
tion of drug effects (for example, weight gain) as well as
individual host factors, such as race, family history, dis-
ease or lifestyle. The part played by antipsychotic medica-
tion in the development of diabetes mellitus is an
ongoing focus of research. Apart from increased adiposity,
there are still unanswered questions about the mechanism
of action involved in altering insulin sensitivity or secre-
tion by these agents [5,6].
We present a patient with paranoid schizophrenia who
developed type 2 diabetes whilst on treatment with SGAS.
He suffered hypoglycaemic episodes on two separate
occasions when the treatment was changed to aripipra-
zole with no change to his antidiabetic treatment.
Case presentation
The patient, a 50-year-old Asian man diagnosed with par-
anoid schizophrenia when in his late twenties, had been
treated with a variety of first generation antipsychotics for
several years. Whilst an inpatient at age 42 years, he had
been prescribed SGAS. He was medically fit, apart from
suffering from hypertension controlled with perindropril
4 mg/day. He was discharged once clinically stable on
olanzapine 20 mg/day. His records revealed that at age 48
years, whilst on 20 mg olanzapine, his random glucose
levels were 17.6 and his glycosylated haemoglobin was
10.9%. He was started on oral hypoglycaemic agents by
his general practitioner, a combination of gliclazide MR
30 mg/day and metformin 500 mg twice daily, which was
later increased to 1 g twice daily because of poor response.
His diabetes mellitus was under control, but as his mental
state continued to deteriorate, olanzapine was increased
to 25 mg/day and subsequently changed to aripiprazole
reaching a dose of 20 mg/day. After 2 months, the patient
experienced gradual weight loss associated with episodes
of hypoglycaemia. Gliclazide was consequently discontin-
ued and he remained on metformin 1 g twice daily.
The patient was re-admitted to hospital 7 months later
owing to poor compliance with medication and exacerba-
tion of his psychiatric symptoms. Whilst in the commu-
nity, his general practitioner restarted his diabetic
medication (gliclazide 30 mg/day and metformin 500 mg
twice daily) and combined it with a lipid-regulating drug
(simvastatin 20 mg/day) and antihypertensive treatment
(amlodipine 10 mg/day and perindropril 4 mg/day). On
admission, his fasting glucose levels were between 3.7 and
6 mmol/l and he was overweight with a body mass index
(BMI) of 27. Risperidone was added to the medication
regime reaching a dose of 6 mg/day. His fasting glucose
levels were between 4.2 mmol/l and 6 mmol/l. After 3
months, despite controlling his psychiatric symptoms, ris-
peridone use resulted in intolerable side effects in the
form of urinary incontinence, therefore it was discontin-
ued and aripiprazole restarted reaching a dose of 15 mg
daily. Six weeks later, the patient presented with sympto-
matic episodes of hypoglycaemia with fasting glucose lev-
els between 2.1 and 3 mmol/l with no changes in body
composition or other metabolic parameters. In consulta-
tion with his diabetologist, the oral hypoglycaemic medi-
cation was discontinued. The patient remained physically
well with fasting glucose levels within normal range (3.5
to 6 mmol/l) during the 6 months that he remained in the
unit.
Discussion
The majority of studies indicate that SGA drugs which
induce more weight gain (for example, clozapine and
olanzapine) are associated with increased risk of diabetes
mellitus and interpretations in the literature in relation to
specific differences among these drugs have been contro-
versial [7]. The increased prevalence of abnormalities in
glucose regulation (for example, insulin resistance) and
under-diagnosis of type 2 diabetes in patients with schiz-
ophrenia, prior to the commencement of antipsychotic
medication, is a confounding factor [4,6]. In addition, the
issue is complicated by the nature (mostly retrospective)
and heterogeneity of the data with studies funded prima-
rily by pharmaceutical companies [6,7].
Differing weight gain risk across the SGA agents seems to
run alongside the variation in relative risk for metabolic
disturbances [7]. One of the proposed mechanisms
appears to be related to a greater H1 histamine receptor
affinity associated with complex interplay among many
other receptors (alpha1, H1, muscarinic, 5 hydroxytryp-
tamine type 2A-2C and so on). Increased adiposity is
linked to decrease in insulin sensitivity and changes in
plasma glucose and lipid levels [6,8]. Emerging evidence
in animal studies suggests that direct drug effects on beta-
cell function and insulin action could be involved as fac-
tors independent from changes in body composition in
up to a quarter of treatment-related new onset diabetes
[7,9]. Rapid induction of hyperglycaemia sometimes
accompanied by ketoacidosis has been reported in
patients on clozapine and olanzapine without weight gain
[9]. It seems likely that the hepatic insulin resistance
develops with acute dosing, whereas weight gain and
hyperlipidemia occur following repeated dosing. An alter-
native mechanism is inhibition of glucose transport into
peripheral tissues, with suppression of cholinergic-stimu-
lated insulin secretion by direct action on the pancreas,
which involves antagonism of muscarinic M3 on beta-
cells [6,9]. In addition, it is likely that the central nervous
system plays an important role through the hypothalamusJournal of Medical Case Reports 2008, 2:155 http://www.jmedicalcasereports.com/content/2/1/155
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and its action over sympathetic and parasympathetic
pathways on glucose regulation [6,8].
Data on the metabolic impact of aripiprazole suggest that
it has little or no detrimental effect relative to other SGAs.
However, two cases of diabetic ketoacidosis were reported
in people with schizophrenia after starting aripiprazole
[10-12] and further reports claim that it may even have a
favourable impact on metabolic parameters [12]. The
debate is still ongoing as a result of fewer long-term data
owing to the limited time this medication has been on the
market.
Our patient, who has diabetes treated with oral hypogly-
caemic agents, experienced changes in body composition
such as gradual weight loss and reversal of metabolic
parameters towards normal levels associated with
hypoglycaemia when the antipsychotic medication he
was on was switched to aripiprazole for the first time.
When his antipsychotic medication was changed to arip-
iprazole once again ten months later, following the dis-
continuation of risperidone owing to side effects, a second
episode of hypoglycaemia occurred. On both occasions
this led to review of his antidiabetic treatment. The
hypoglycaemic episode could be explained by the discon-
tinuation of olanzapine and/or risperidone as described
in the literature [13] or the combination of oral hypogly-
caemic medication with aripiprazole. However, it is rele-
vant to note that the patient did not require any
antidiabetic treatment whilst on aripiprazole during the
follow up period.
Conclusion
Clinicians face regular dilemmas in trying to find the right
balance between achieving control over the patient's men-
tal illness and reducing the adverse effects associated with
the prescribed medication. Whilst research in the area is
ongoing, psychiatrists should perform regular general
health monitoring (including screening for diabetes mel-
litus) in all patients with schizophrenia. In patients receiv-
ing concomitant antidiabetic therapy, caution should be
exercised when changing from one SGA to another. Whilst
more longitudinal data is required, a trial of alternative
SGAs, including aripiprazole in those developing type 2
diabetes and impaired glucose tolerance may be a worth-
while therapeutic option.
Further research is required to determine the potential of
aripiprazole to prevent complications or reverse meta-
bolic abnormalities in those patients with pronounced
disturbances at baseline. If present, these properties could
enhance treatment options in patients receiving concom-
itant antidiabetic therapy and in those patients with treat-
ment resistance on combination therapy with drugs
known to have a poor safety profile [14].
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